Signal Transduction and Targeted Therapy

{{Infobox journal

| title = Signal Transduction and Targeted Therapy

| image =

| image_size =

| alt =

| caption =

| former_name =

| abbreviation = Signal Transduct. Target. Ther.

| discipline = {{hlist|Biomedicine|Pharmacology}}

| peer-reviewed =

| language = English

| editor = {{hlist|Carlo M. Croce|Kang Zhang|Yu-Quan Wei}}

| publisher = Nature Research

| country =

| history = 2016–present

| frequency = Continuous

| openaccess = Yes

| license =

| impact = 40.8

| impact-year = 2023

| bluebook =

| mathscinet =

| nlm =

| ISSN = 2095-9907

| ISSNlabel =

| eISSN = 2059-3635

| CODEN =

| JSTOR =

| LCCN = 2016243461

| OCLC = 1026877558

| website = https://www.nature.com/sigtrans/

| link1 = https://www.nature.com/sigtrans/research-articles

| link1-name = Online archive

}}

Signal Transduction and Targeted Therapy is a multidisciplinary peer-reviewed open access scientific journal covering biomedical research with a particular focus on signal transduction and its application to the drug development process. It was established in 2016 and is published by Nature Research. The editors-in-chief are Carlo M. Croce (Ohio State University), Kang Zhang (Macau University of Science and Technology), and Yu-Quan Wei (West China Medical Center). According to the Journal Citation Reports, the journal has a 2023 impact factor of 40.8.{{cite book |year=2023 |chapter=Signal Transduction and Targeted Therapy |title=2023 Journal Citation Reports |publisher=Clarivate Analytics |edition=Science |series=Web of Science}}